Acetic Acid

Acetic Acid

SCHEMBL444058

CC(=O)O.CCOC(=O)C(=O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
LMNA P02545 1/20 0.52
HSD17B10 Q99714 1/20 0.52
GLO1 Q04760 1/20 0.50
EGLN1 Q9GZT9 1/20 0.46
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 1/20 0.44
ALOX15 P16050 1/20 0.43
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
SOAT1 P35610 1/20 0.43
CYP2D6 P10635 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HCAR2 Q8TDS4 1/20 0.41
TRPA1 O75762 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL11592444 0.97 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10GLO1EGLN1
Acetone SCHEMBL7709105 0.94 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10GLO1EGLN1
SCHEMBL98770 0.94
Ammonia Solution, Strong SCHEMBL27437639 0.92
Oxalic Acid SCHEMBL27581908 0.92 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10GLO1EGLN1
SCHEMBL29240048 0.92
Fluoride SCHEMBL27810482 0.92
Hydrochloric Acid SCHEMBL943803 0.92
SCHEMBL28863989 0.92
SCHEMBL27705013 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000788-A1 METHOD FOR DRY POWDER COATING CAPSULES NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) 2022-01-06 US claimed
US-20200222330-A1 METHOD FOR DRY POWDER COATING CAPSULES POWDER PHARMA COATING INC. (CA) 2020-07-16 US claimed
US-20190099377-A1 METHOD FOR DRY POWDER COATING OSMOTIC DRUG DELIVERY SYSTEM NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) 2019-04-04 US claimed
US-20190099378-A1 METHOD FOR DRY POWDER COATING CAPSULES NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) 2019-04-04 US claimed
EP-2305624-B1 Self-degradable explosive device MAXAMCORP HOLDING SL (ES) 2017-09-27 EP claimed
US-8585841-B2 Systems and methods for chemical and/or mechanical remediation of nitro compounds and nitrate esters MAXAMCORP HOLDING S.L. (ES) 2013-11-19 US claimed
US-8529955-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2013-09-10 US claimed
US-8440232-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2013-05-14 US claimed
EP-2445852-A1 SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS Maxamcorp Holding, S.L. (ES) 2012-05-02 EP claimed
US-20120064168-A1 METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE DEPOMED, INC. (US) 2012-03-15 US claimed
US-20040175428-A1 Controlled release by extrusion of solid amorphous dispersions of drugs PFIZER INC. 2004-09-09 US claimed
US-20040137156-A1 Coated solid dosage form and method for preparing same LEE ERNEST J 2004-07-15 US claimed
WO-2004050066-A1 MICROSPHERES AND RELATED PROCESSES AND PHARMACEUTICAL COMPOSITIONS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2004-06-17 WO claimed
US-6706283-B1 INCREASING BIOAVAILABILITY OF SPARINGLY WATER SOLUBLE ACTIVE INGREDIENTS; CONTROLLED INFLUX OF WATER TO CORE USING NON-DISSOLVING, NONERODING COATING PFIZER INC 2004-03-16 US claimed
WO-2004010982-A1 METHOD OF PREPARING SOLID DOSAGE FORMS COATED IN TWO LAYERS COMPRISING A WATER-INSOLUBLE POLYMER AND A WATER-SOLUBLE PORE FORMER PHARMACIA CORPORATION (US) 2004-02-05 WO claimed
WO-2003092660-A1 MONOCOMPARTMENT OSMOTIC CONTROLLED DRUG DELIVERY SYSTEM RANBAXY LABORATORIES LIMITED (US) 2003-11-13 WO claimed
EP-1027888-A2 Osmotic system for delivery of solid amorphous dispersions of drugs Pfizer Products Inc. (US) 2000-08-16 EP claimed
US-5612059-A CELLULOSE DERIVATIVE, DRUG DELIVERY PFIZER INC. (US) 1997-03-18 US claimed
US-5458887-A OF AN OSMOTIC CORE CONTAINING A DRUG AND A WATER SWELLABLE COMPONENT AND A WATER RESISTANT POLYMER COATING CONTAINING A COMPOUND WHICH DISSOLVES IN GASTROINTESTINAL FLUID ANDRX PHARMACEUTICALS, INC. (US) 1995-10-17 US claimed
EP-0326727-A1 Sustained release implant and method for preparing same INTERNATIONAL MINERALS AND CHEMICAL CORPORATION (US) 1989-08-09 EP claimed